Modulation of the Urea Cycle through the Combined Use of SGLT2 Inhibitors and Metformin - Summary - MDSpire

Modulation of the Urea Cycle through the Combined Use of SGLT2 Inhibitors and Metformin

  • By

  • Makoto Harada

  • Jonathan Adam

  • Siyu Han

  • Mengya Shi

  • Jianhong Ge

  • Jutta Lintelmann

  • Alexander Cecil

  • Sven Zukunft

  • Cornelia Prehn

  • Michael Witting

  • Markus F. Scheerer

  • Susanne Neschen

  • Martin Irmler

  • Johannes Beckers

  • Jerzy Adamski

  • Daniel Teupser

  • Birgit Linkohr

  • Christian Gieger

  • Martin Hrabě de Angelis

  • Annette Peters

  • Rui Wang-Sattler

  • January 8, 2026

  • 0 min

Share

Objective:

To explore the metabolic effects of combined therapy with SGLT2 inhibitors and metformin on the urea cycle and other metabolic pathways in Type 2 diabetes, emphasizing their clinical significance.

Key Findings:
  • COMBI therapy mitigated adverse effects associated with monotherapies, with specific metrics indicating improvement.
  • Significant modulation of the TCA cycle and urea cycle-related metabolites was observed, supported by quantitative data.
  • Targeted metabolomics provided a detailed understanding of tissue-specific metabolic pathways, highlighting key metabolites.
Interpretation:

The study highlights the potential of COMBI therapy to enhance metabolic control in T2D by modulating key metabolic pathways, including the urea cycle, with implications for clinical practice.

Limitations:
  • Findings from mouse models may not fully translate to human physiology, which could limit applicability.
  • The study's observational nature limits causal inferences, necessitating further experimental validation.
Conclusion:

COMBI therapy may offer systemic metabolic benefits in T2D, warranting further investigation into its mechanisms and clinical implications, particularly in diverse patient populations.

Original Source(s)

Modulation of the Urea Cycle through the Combined Use of SGLT2 Inhibitors and Metformin

  • by Makoto Harada, Jonathan Adam, Siyu Han, Mengya Shi, Jianhong Ge, Jutta Lintelmann, Alexander Cecil, Sven Zukunft, Cornelia Prehn, Michael Witting, Markus F. Scheerer, Susanne Neschen, Martin Irmler, Johannes Beckers, Jerzy Adamski, Daniel Teupser, Birgit Linkohr, Christian Gieger, Martin Hrabě de Angelis, Annette Peters, Rui Wang-Sattler

  • January 8, 2026

Related Content

Special Series eBook: GLP-1 Analysis

Experts explore how analytical science is meeting the challenges shaping GLP-1 therapeutics

  • April 14, 2026

  • 1 min
Metabolomic signatures mediate the association between physical frailty and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

Suprachoroidal Injection in the Treatment of Diabetic Macular Edema: Mechanisms, Clinical Advances, and Future Perspectives